8-K
MANHATTAN ASSOCIATES INC (MANH)
United States
Securities And Exchange Commission
Washington, DC 20549
______________
FORM 8-K
____________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 16, 2025
Manhattan Associates, Inc.
(Exact Name of Registrant as Specified in Its Charter)
| Georgia | 0-23999 | 58-2373424 |
|---|---|---|
| (State or Other Jurisdiction of<br>Incorporation or organization) | (Commission<br>File Number) | (I.R.S. Employer<br>Identification No.) |
2300 Windy Ridge Parkway, Tenth Floor, Atlanta, Georgia
30339
(Address of Principal Executive Offices)
(Zip Code)
(770) 955-7070
(Registrant’s telephone number, including area code)
NONE
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br><br>Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common stock | MANH | Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On April 22, 2025, Manhattan Associates, Inc. (“we”, “our”, or the “Company”) issued a press release providing its financial results for the three months ended March 31, 2025. A copy of this press release is attached as Exhibit 99.1. Pursuant to General Instruction B.2 of Form 8-K, this exhibit is “furnished” and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934.
Non-GAAP Financial Measures in the Press Release
The press release includes, as additional information regarding our operating results, our adjusted operating income and margin, adjusted income tax provision, adjusted net income and adjusted diluted earnings per share (collectively, “adjusted results”), which exclude the impact of equity-based compensation, expense related to an unusual health insurance claim, net of insurance recoveries, restructuring expense, and related income tax effects. We have excluded these expenses from our internal assessment of our operating performance.
These various measures are not in accordance with, or alternatives for, financial measures calculated in accordance with generally accepted accounting principles in the United States (“GAAP”) and may be different from similarly titled non-GAAP financial measures used by other companies. Non-GAAP financial measures should not be used as a substitute for, or considered superior to, measures of financial performance prepared in accordance with GAAP.
Non-GAAP measures used in the press release exclude the impact of the items described above for the following reasons:
- Equity-Based Compensation: Equity-based compensation expense typically does not require cash settlement by the Company. We also exclude the tax benefits or deficiencies of vested stock awards caused by differences in the amount deductible for tax purposes related to the stock award from the compensation expense recorded for financial reporting purposes.
- Unusual Health Insurance Claim, Net of Insurance Recoveries: Due to the uncommonly large magnitude and nature of the health insurance claim, we do not believe that this expense is a typical cost that results from normal operating activities.
- Restructuring Expense: We do not believe that the restructuring expense related to a reduction in our workforce recorded in the first quarter of 2025 is a common cost that results from normal operating activities; rather, it relates to aligning our services capacity with customer demand which has been impacted by short-term macro-economic uncertainty.
We assess our operating performance using these adjusted measures and believe our peers also typically present non-GAAP results similarly adjusted. Further, we rely on adjusted results as primary measures to review and assess the operating performance of our management team in connection with our executive compensation and bonus plans.
Management refers to adjusted results in making operating decisions because we believe they provide meaningful supplemental information regarding our operational performance and our ability to invest in research and development and fund capital expenditures and acquisitions. In addition, adjusted results facilitate management’s internal comparisons to our historical operating results and comparisons to competitors’ operating results.
We similarly believe reporting adjusted results facilitates investors’ understanding of our historical operating trends because it provides supplemental measurement information in evaluating the operating results of our business. We also believe that adjusted results provide a basis for comparisons to
other companies in the industry and enable investors to evaluate our operating performance in a manner consistent with our internal basis of measurement.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Election of New Director
On April 16, 2025, the Board of Directors (the “Board”) of the Company elected Ms. Danielle Sheer to serve as a member of the Board, as a Class II director, and appointed her to serve on the Nomination and Governance Committee, both effective as of May 13, 2025. Ms. Sheer initially will serve the remainder of the term of co-founder and long-term director Mr. Deepak Raghavan, who is retiring as of May 13, 2025.
Ms. Sheer, 44, serves as the Chief Trust Officer of Commvault (NASDAQ: CVLT), a leader in cyber resilience and data protection. She leads the company’s business development, corporate development, cybersecurity, and governance programs. Previously, Ms. Sheer served as Chief Legal Officer of Bottomline Technologies (NASDAQ: EPAY), a leading provider of financial technology for business payments. Bottomline sold to private equity firm Thoma Bravo in a take-private transaction. Prior to Bottomline, Ms. Sheer led Carbonite through its initial public offering and NASDAQ listing in 2011 (NASDAQ: CARB), successfully defending against patent troll litigations, a hostile takeover attempt and activist shareholders. Carbonite sold to OpenText in a take-private transaction (NASDAQ: OTEX). Ms. Sheer currently serves on the Board of Directors of Beth Israel Deaconess Medical Center, a world-class teaching hospital of Harvard Medical School; as Global Chair of the L Suite, a private community of high-tech Chief Legal Officers; and Linksquares, an AI-powered CLM solution. She also serves on advisory boards for BreachRX, a cyber incident response management platform; and Formally, an AI-driven platform that streamlines the U.S. immigration process. Corporate Counsel has recognized her as one of the most Innovative Women in Law, and earlier in her career by Boston Business Journal and Massachusetts Bar Association as an "Emerging Leader" and "Maverick of the Year" for Women in Business. She holds a J.D. from Georgetown University Law Center and a B.A. from George Washington University.
Ms. Sheer will receive compensation in accordance with the Company’s existing compensation policy for non-employee directors. Ms. Sheer was not elected pursuant to any arrangement or understanding between her and any other person. Ms. Sheer has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit | |
|---|---|
| Number | Description |
| 99.1 | Press Release, dated April 22, 2025 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
Manhattan Associates, Inc.
By: /s/ Dennis B. Story
Dennis B. Story
Executive Vice President, Chief Financial Officer and Treasurer
Dated: April 22, 2025
EX-99.1
Exhibit 99.1
| Contact: | Michael Bauer | Devika Goel |
|---|---|---|
| Senior Director,<br><br>Investor Relations | Senior Manager,<br><br>Public Relations | |
| Manhattan Associates, Inc. | Manhattan Associates, Inc. | |
| 678-597-7538 | 678-597-6754 | |
| mbauer@manh.com | dgoel@manh.com |
Manhattan Associates Reports First Quarter Results
RPO Bookings Increased 25% over Prior Year
ATLANTA – April 22, 2025 – Leading Supply Chain and Omnichannel Commerce Solutions provider Manhattan Associates Inc. (NASDAQ: MANH) today reported revenue of $262.8 million for the first quarter ended March 31, 2025. GAAP diluted earnings per share for Q1 2025 was $0.85 compared to $0.86 in Q1 2024. Non-GAAP adjusted diluted earnings per share for Q1 2025 was $1.19 compared to $1.03 in Q1 2024.
“Manhattan is off to a solid start to 2025 and delivered better than expected top and bottom line first quarter results,” said Manhattan Associates president and CEO Eric Clark.
“Since joining Manhattan, I have been impressed by our platform, products, and people. Our unified cloud portfolio offers best-in-class functionality and Manhattan is the only cloud provider named by industry analysts as a leader across the supply chain commerce ecosystem. Our addressable market is large and growing, and we are well positioned for success across a broad set of industries,” Mr. Clark concluded.
FIRST QUARTER 2025 FINANCIAL SUMMARY:
Consolidated total revenue was $262.8 million for Q1 2025, compared to $254.6 million for Q1 2024.
Cloud subscription revenue was $94.3 million for Q1 2025, compared to $78.0 million for Q1 2024.
License revenue was $9.3 million for Q1 2025, compared to $2.8 million for Q1 2024.
Services revenue was $121.1 million for Q1 2025, compared to $132.2 million for Q1 2024.
GAAP diluted earnings per share was $0.85 for Q1 2025, compared to $0.86 for Q1 2024.
Adjusted diluted earnings per share, a non-GAAP measure, was $1.19 for Q1 2025, compared to $1.03 for Q1 2024.
GAAP operating income was $63.2 million for Q1 2025, compared to $57.6 million for Q1 2024.
Adjusted operating income, a non-GAAP measure, was $91.3 million for Q1 2025, compared to $79.7 million for Q1 2024.
Cash flow from operations was $75.3 million for Q1 2025, compared to $54.7 million for Q1 2024. Days Sales Outstanding was 72 days at March 31, 2025, compared to 74 days at December 31, 2024.
Cash totaled $205.9 million at March 31, 2025, compared to $266.2 million at December 31, 2024.
During the three months ended March 31, 2025, the Company repurchased 539,328 shares of Manhattan Associates common stock under the share repurchase program authorized by our Board of Directors for a total investment of $100.0 million. In April 2025, our Board of Directors approved replenishing the Company’s remaining share repurchase authority to an aggregate of $100.0 million of our common stock.
2025 GUIDANCE
Manhattan Associates provides the following revenue, operating margin and diluted earnings per share guidance for the full year 2025:
| Guidance Range - 2025 Full Year | |||
|---|---|---|---|
| ($'s in millions, except operating margin and EPS) | Range | % Growth Range | |
| Total revenue | 1,060 | 2% | 3% |
| Operating Margin: | |||
| GAAP operating margin | 22.5% | ||
| Equity-based compensation | 9.8% | ||
| Unusual health insurance claim(3) | 0.4% | ||
| Restructuring expense(4) | 0.3% | ||
| Adjusted operating margin(1) | 33.0% | ||
| Diluted earnings per share (EPS): | |||
| GAAP EPS | 3.06 | -13% | -10% |
| Equity-based compensation | 1.45 | ||
| Excess tax benefit on stock vesting(2) | (0.06) | ||
| Unusual health insurance claim(3) | 0.05 | ||
| Restructuring expense(4) | 0.04 | ||
| Adjusted EPS(1) | 4.54 | -4% | -2% |
| (1) Adjusted operating margin and adjusted EPS are non-GAAP measures that exclude the impact of equity-based compensation, | |||
| expense related to an unusual health insurance claim, restructuring expense, and the related income tax effects, if applicable. | |||
| (2) Excess tax benefit on stock vesting expected to occur primarily in the first quarter of 2025. | |||
| (3) Adjustment represents expense for an unusual health insurance claim, net of insurance recoveries. Based on the uncommonly large magnitude and nature of the claim, we do not believe that this expense reflects our normal operating activities, and we have excluded the amount from adjusted non-GAAP results. | |||
| (4) In January 2025, the Company eliminated about 100 positions to align our services capacity with customer demand, which has been impacted by short-term macro-economic uncertainty. We recorded a pre-tax restructuring expense in the first quarter of 2025 and exclude the amount from adjusted non-GAAP results. |
All values are in US Dollars.
Manhattan Associates currently intends to publish in each quarterly earnings release certain expectations with respect to future financial performance. Those statements, including the guidance provided above, are forward looking. Actual results may differ materially. See our cautionary note regarding “forward-looking statements” below.
Manhattan Associates will make this earnings release and published expectations available on the investor relations section of the Manhattan Associates website at ir.manh.com. Following publication of this earnings release, any expectations with respect to future financial performance contained in this release, including the guidance, should be considered historical only, and Manhattan Associates disclaims any obligation to update them.
CONFERENCE CALL
Manhattan Associates’ conference call regarding its first quarter financial results will be held today, April 22, 2025, at 4:30 p.m. Eastern Time. The Company will also discuss its business and expectations for the year and next quarter in additional detail during the call. We invite investors to a live webcast of the conference call through the Investor Relations section of the Manhattan Associates website at ir.manh.com. To listen to the live webcast, please go to the website at least 15 minutes before the call to download and install any necessary audio software. The Internet webcast will be available until Manhattan Associates’ second quarter 2025 earnings release.
GAAP VERSUS NON-GAAP PRESENTATION
Manhattan Associates provides adjusted operating income and margin, adjusted income tax provision, adjusted net income, and adjusted diluted earnings per share in this press release as additional information regarding the Company’s historical and projected operating results. These measures are not in accordance with, or alternatives to, GAAP, and may be different from similarly titled non-GAAP measures used by other companies. The Company believes the presentation of these non-GAAP financial measures facilitates investors’ ability to understand and compare the Company’s results and guidance, because the measures provide supplemental information in evaluating the operating results of its business, as distinct from results that include items not indicative of ongoing operating results, and because the Company believes its peers typically publish similar non-GAAP measures. This release should be read in conjunction with the Company’s Form 8-K earnings release filing for the three months ended March 31, 2025.
Non-GAAP adjusted operating income and margin, adjusted income tax provision, adjusted net income and adjusted diluted earnings per share exclude the impact of equity-based compensation, an expense related to an unusual health insurance claim, and restructuring expense – net of income tax effects, collectively. They also exclude the tax benefits or deficiencies of vested stock awards caused by differences in the amount deductible for tax purposes from the compensation expense recorded for financial reporting purposes. We include reconciliations of the Company’s GAAP financial measures to non-GAAP adjustments in the supplemental information attached to this release.
ABOUT MANHATTAN ASSOCIATES
Manhattan Associates is a global technology leader in supply chain and omnichannel commerce. We unite information across the enterprise, converging front-end sales with back-end supply chain execution. Our software, platform technology and unmatched experience help drive both top-line growth and bottom-line profitability for our customers.
Manhattan Associates designs, builds and delivers leading edge cloud solutions so that across the store, through your network or from your fulfillment center, you are ready to reap the rewards of the omnichannel marketplace. For more information, please visit www.manh.com.
This press release contains “forward-looking statements” relating to Manhattan Associates, Inc. Forward-looking statements in this press release include, without limitation, the information set forth under “2025 Guidance” and statements identified by words such as “may,” “expect,” “forecast,” “anticipate,” “intend,” “plan,” “believe,” “could,” “seek,” “project,” “estimate” and similar expressions. Prospective investors are cautioned that any of those forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by those forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated by those forward-looking statements are: economic conditions, including disruption and transformation in the retail sector and our vertical markets; delays in product development; competitive and pricing pressures; software errors and information technology failures, disruption and security breaches; risks related to our products’ technology and customer implementations; global instability, including the wars in Ukraine and the Middle East; and the other risk factors set forth in Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and in Item 1A of Part II in subsequent Quarterly Reports on Form 10-Q. Manhattan Associates undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results.
MANHATTAN ASSOCIATES, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Income
(in thousands, except per share amounts)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| (unaudited) | (unaudited) | |
| Revenue: | ||
| Cloud subscriptions | $94,306 | $78,027 |
| Software license | 9,292 | 2,810 |
| Maintenance | 32,144 | 34,972 |
| Services | 121,127 | 132,195 |
| Hardware | 5,918 | 6,548 |
| Total revenue | 262,787 | 254,552 |
| Costs and expenses: | ||
| Cost of cloud subscriptions, maintenance and services | 114,358 | 118,955 |
| Cost of software license | 209 | 332 |
| Research and development | 35,298 | 35,010 |
| Sales and marketing | 21,061 | 19,929 |
| General and administrative | 24,219 | 21,203 |
| Depreciation and amortization | 1,541 | 1,493 |
| Restructuring expense | 2,929 | - |
| Total costs and expenses | 199,615 | 196,922 |
| Operating income | 63,172 | 57,630 |
| Other income, net | 1,337 | 996 |
| Income before income taxes | 64,509 | 58,626 |
| Income tax provision | 11,927 | 4,825 |
| Net income | $52,582 | $53,801 |
| Basic earnings per share | $0.86 | $0.87 |
| Diluted earnings per share | $0.85 | $0.86 |
| Weighted average number of shares: | ||
| Basic | 60,870 | 61,625 |
| Diluted | 61,527 | 62,493 |
Reconciliation of Selected GAAP to Non-GAAP Measures
(in thousands, except per share amounts)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating income | $63,172 | $57,630 |
| Equity-based compensation (a) | 28,826 | 22,095 |
| Unusual health insurance claim (c) | (3,658) | - |
| Restructuring expense (d) | 2,929 | - |
| Adjusted operating income (Non-GAAP) | $91,269 | $79,725 |
| Income tax provision | $11,927 | $4,825 |
| Equity-based compensation (a) | 4,340 | 3,436 |
| Tax benefit of stock awards vested (b) | 3,542 | 8,157 |
| Unusual health insurance claim (c) | (883) | - |
| Restructuring expense (d) | 707 | - |
| Adjusted income tax provision (Non-GAAP) | $19,633 | $16,418 |
| Net income | $52,582 | $53,801 |
| Equity-based compensation (a) | 24,486 | 18,659 |
| Tax benefit of stock awards vested (b) | (3,542) | (8,157) |
| Unusual health insurance claim (c) | (2,775) | - |
| Restructuring expense (d) | 2,222 | - |
| Adjusted net income (Non-GAAP) | $72,973 | $64,303 |
| Diluted EPS | $0.85 | $0.86 |
| Equity-based compensation (a) | 0.40 | 0.30 |
| Tax benefit of stock awards vested (b) | (0.06) | (0.13) |
| Unusual health insurance claim (c) | (0.05) | - |
| Restructuring expense (d) | 0.04 | - |
| Adjusted diluted EPS (Non-GAAP) | $1.19 | $1.03 |
| Fully diluted shares | 61,527 | 62,493 |
- Adjusted results exclude all equity-based compensation, as detailed below, to facilitate comparison with our peers and for the other reasons explained in our Current Report on Form 8-K filed with the SEC. We do not receive a GAAP tax benefit for a portion of our equity-based compensation, mainly because of Section 162(m) of the Internal Revenue Code, which limits tax deductions for compensation granted to certain executives.
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cost of services | $11,425 | $9,289 |
| Research and development | 5,958 | 5,240 |
| Sales and marketing | 2,306 | 1,990 |
| General and administrative | 9,137 | 5,576 |
| Total equity-based compensation | $28,826 | $22,095 |
Adjustments represent the excess tax benefits and tax deficiencies of the equity awards vested during the period. Excess tax benefits (deficiencies) occur when the amount deductible on our tax return for an equity award is more (less) than the cumulative compensation cost recognized for financial reporting purposes. As discussed above, we exclude equity-based compensation from adjusted non-GAAP results to be consistent with other companies in the software industry and for the other reasons explained in our Current Report on Form 8-K filed with the SEC. Therefore, we also exclude the related tax benefit (expense) generated upon their vesting.
In the fourth quarter of 2024, we recorded $7.0 million of expense for an unusual health insurance claim. During the first quarter of 2025, we received an insurance recovery of $4.7 million for this claim, partially offset by additional ongoing expense for the claim. Based on the uncommonly large magnitude and nature of the claim, we do not believe that this expense reflects our normal operating activities, and we have excluded the amount from adjusted non-GAAP results.
In January 2025, the Company eliminated about 100 positions to align our services capacity with customer demand, which has been impacted by short-term macro-economic uncertainty. We recorded pre-tax restructuring expense in the first quarter of 2025 of approximately $2.9 million. The expense primarily consists of employee severance and outplacement services. We do not believe that the expense is a common cost that resulted from normal operating activities, and thus we have excluded the amount from adjusted non-GAAP results.
MANHATTAN ASSOCIATES, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
| December 31, 2024 | |||||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current assets: | |||||
| Cash and cash equivalents | 205,873 | $ | 266,230 | ||
| Accounts receivable, net | 210,694 | 205,475 | |||
| Prepaid expenses and other current assets | 38,768 | 31,559 | |||
| Total current assets | 455,335 | 503,264 | |||
| Property and equipment, net | 13,508 | 13,971 | |||
| Operating lease right-of-use assets | 48,366 | 47,923 | |||
| Goodwill, net | 62,232 | 62,226 | |||
| Deferred income taxes | 92,389 | 94,505 | |||
| Other assets | 36,391 | 35,662 | |||
| Total assets | 708,221 | $ | 757,551 | ||
| LIABILITIES AND SHAREHOLDERS' EQUITY | |||||
| Current liabilities: | |||||
| Accounts payable | 24,199 | $ | 26,615 | ||
| Accrued compensation and benefits | 54,873 | 72,180 | |||
| Accrued and other liabilities | 25,976 | 22,275 | |||
| Deferred revenue | 296,583 | 277,970 | |||
| Income taxes payable | 3,385 | 1,264 | |||
| Total current liabilities | 405,016 | 400,304 | |||
| Operating lease liabilities, long-term | 46,999 | 47,794 | |||
| Other non-current liabilities | 11,111 | 10,327 | |||
| Shareholders' equity: | |||||
| Preferred stock, no par value; 20,000,000 shares authorized, no shares issued or outstanding in 2025 and 2024 | - | - | |||
| Common stock, 0.01 par value; 200,000,000 shares authorized; 60,714,813 and 60,921,191 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively | 607 | 609 | |||
| Retained earnings | 274,078 | 329,439 | |||
| Accumulated other comprehensive loss | (29,590 | ) | (30,922 | ) | |
| Total shareholders' equity | 245,095 | 299,126 | |||
| Total liabilities and shareholders' equity | 708,221 | $ | 757,551 |
All values are in US Dollars.
MANHATTAN ASSOCIATES, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||||||
|---|---|---|---|---|---|---|
| 2025 | 2024 | |||||
| (unaudited) | (unaudited) | |||||
| Operating activities: | ||||||
| Net income | $ | 52,582 | $ | 53,801 | ||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||
| Depreciation and amortization | 1,541 | 1,493 | ||||
| Equity-based compensation | 28,826 | 22,095 | ||||
| Gain on disposal of equipment | (98 | ) | (138 | ) | ||
| Deferred income taxes | 2,133 | (3,869 | ) | |||
| Unrealized foreign currency loss | 781 | 501 | ||||
| Changes in operating assets and liabilities: | ||||||
| Accounts receivable, net | (3,321 | ) | (25,434 | ) | ||
| Other assets | (11,959 | ) | (4,520 | ) | ||
| Accounts payable, accrued and other liabilities | (18,807 | ) | (20,809 | ) | ||
| Income taxes | 6,482 | 4,594 | ||||
| Deferred revenue | 17,100 | 27,024 | ||||
| Net cash provided by operating activities | 75,260 | 54,738 | ||||
| Investing activities: | ||||||
| Purchase of property and equipment | (891 | ) | (2,321 | ) | ||
| Net cash used in investing activities | (891 | ) | (2,321 | ) | ||
| Financing activities: | ||||||
| Repurchase of common stock | (136,447 | ) | (113,834 | ) | ||
| Net cash used in financing activities | (136,447 | ) | (113,834 | ) | ||
| Foreign currency impact on cash | 1,721 | (1,800 | ) | |||
| Net change in cash and cash equivalents | (60,357 | ) | (63,217 | ) | ||
| Cash and cash equivalents at beginning of period | 266,230 | 270,741 | ||||
| Cash and cash equivalents at end of period | $ | 205,873 | $ | 207,524 |
MANHATTAN ASSOCIATES, INC.
SUPPLEMENTAL INFORMATION
- GAAP and adjusted earnings per share by quarter are as follows:
| 2024 | 2025 | |||||
|---|---|---|---|---|---|---|
| 1st Qtr | 2nd Qtr | 3rd Qtr | 4th Qtr | Full Year | 1st Qtr | |
| GAAP Diluted EPS | $0.86 | $0.85 | $1.03 | $0.77 | $3.51 | $0.85 |
| Adjustments to GAAP: | ||||||
| Equity-based compensation | 0.30 | 0.34 | 0.33 | 0.31 | 1.27 | 0.40 |
| Tax benefit of stock awards vested | (0.13) | (0.01) | (0.01) | - | (0.15) | (0.06) |
| Restructuring expense | - | - | - | - | - | 0.04 |
| Unusual health insurance claim | - | - | - | 0.09 | 0.09 | (0.05) |
| Adjusted Diluted EPS | $1.03 | $1.18 | $1.35 | $1.17 | $4.72 | $1.19 |
| Fully Diluted Shares | 62,493 | 62,118 | 61,948 | 62,009 | 62,183 | 61,527 |
- Revenues and operating income by reportable segment are as follows (in thousands):
| 2024 | 2025 | |||||
|---|---|---|---|---|---|---|
| 1st Qtr | 2nd Qtr | 3rd Qtr | 4th Qtr | Full Year | 1st Qtr | |
| Revenue: | ||||||
| Americas | $196,312 | $205,955 | $205,852 | $194,367 | $802,486 | $194,615 |
| EMEA | 46,620 | 46,918 | 48,082 | 48,903 | 190,523 | 55,542 |
| APAC | 11,620 | 12,445 | 12,747 | 12,531 | 49,343 | 12,630 |
| $254,552 | $265,318 | $266,681 | $255,801 | $1,042,352 | $262,787 | |
| GAAP Operating Income: | ||||||
| Americas | $36,687 | $45,300 | $49,033 | $36,323 | $167,343 | $33,862 |
| EMEA | 15,884 | 17,195 | 20,521 | 18,896 | 72,496 | 23,703 |
| APAC | 5,059 | 5,693 | 5,536 | 5,469 | 21,757 | 5,607 |
| $57,630 | $68,188 | $75,090 | $60,688 | $261,596 | $63,172 | |
| Adjustments (pre-tax): | ||||||
| Americas: | ||||||
| Equity-based compensation | $22,095 | $24,666 | $23,853 | $22,592 | $93,206 | $28,826 |
| Unusual health insurance claim | - | - | - | 7,002 | 7,002 | (3,658) |
| Restructuring expense | - | - | - | - | - | 2,929 |
| $22,095 | $24,666 | $23,853 | $29,594 | $100,208 | $28,097 | |
| Adjusted non-GAAP Operating Income: | ||||||
| Americas | $58,782 | $69,966 | $72,886 | $65,917 | $267,551 | $61,959 |
| EMEA | 15,884 | 17,195 | 20,521 | 18,896 | 72,496 | 23,703 |
| APAC | 5,059 | 5,693 | 5,536 | 5,469 | 21,757 | 5,607 |
| $79,725 | $92,854 | $98,943 | $90,282 | $361,804 | $91,269 |
- Impact of Currency Fluctuation
The following table reflects the increases (decreases) in the results of operations for each period attributable to the change in foreign currency exchange rates from the prior period as well as foreign currency gains (losses) included in other income, net for each period (in thousands):
| 2024 | 2025 | |||||
|---|---|---|---|---|---|---|
| 1st Qtr | 2nd Qtr | 3rd Qtr | 4th Qtr | Full Year | 1st Qtr | |
| Revenue | $648 | $(531) | $936 | $316 | $1,369 | $(1,591) |
| Costs and expenses | 176 | (673) | 211 | (227) | (513) | (1,966) |
| Operating income | 472 | 142 | 725 | 543 | 1,882 | 375 |
| Foreign currency gains (losses) in other income | (564) | (577) | (331) | 519 | (953) | 131 |
| $(92) | $(435) | $394 | $1,062 | $929 | $506 |
Manhattan Associates has a large research and development center in Bangalore, India. The following table reflects the increases (decreases) in the financial results for each period attributable to changes in the Indian Rupee exchange rate (in thousands):
| 2024 | 2025 | |||||
|---|---|---|---|---|---|---|
| 1st Qtr | 2nd Qtr | 3rd Qtr | 4th Qtr | Full Year | 1st Qtr | |
| Operating income | $185 | $307 | $261 | $302 | $1,055 | $785 |
| Foreign currency gains (losses) in other income | 164 | 41 | 284 | 1,283 | 1,772 | 15 |
| Total impact of changes in the Indian Rupee | $349 | $348 | $545 | $1,585 | $2,827 | $800 |
- Other income includes the following components (in thousands):
| 2024 | 2025 | |||||
|---|---|---|---|---|---|---|
| 1st Qtr | 2nd Qtr | 3rd Qtr | 4th Qtr | Full Year | 1st Qtr | |
| Interest income | $1,414 | $1,503 | $1,636 | $1,476 | $6,029 | $1,101 |
| Foreign currency gains (losses) | (564) | (577) | (331) | 519 | (953) | 130 |
| Other non-operating income (expense) | 146 | (12) | 7 | 1 | 142 | 106 |
| Total other income (loss) | $996 | $914 | $1,312 | $1,996 | $5,218 | $1,337 |
- Capital expenditures are as follows (in thousands):
| 2024 | 2025 | |||||
|---|---|---|---|---|---|---|
| 1st Qtr | 2nd Qtr | 3rd Qtr | 4th Qtr | Full Year | 1st Qtr | |
| Capital expenditures | $2,321 | $2,217 | $1,009 | $3,128 | $8,675 | $891 |
- Stock Repurchase Activity (in thousands):
| 2024 | 2025 | |||||
|---|---|---|---|---|---|---|
| 1st Qtr | 2nd Qtr | 3rd Qtr | 4th Qtr | Full Year | 1st Qtr | |
| Shares purchased under publicly-announced buy-back program | 294 | 343 | 194 | 156 | 987 | 539 |
| Shares withheld for taxes due upon vesting of restricted stock | 165 | 3 | 8 | 2 | 178 | 179 |
| Total shares purchased | 459 | 346 | 202 | 158 | 1,165 | 718 |
| Total cash paid for shares purchased under publicly-announced buy-back program | $73,411 | $74,999 | $49,687 | $43,539 | $241,636 | $100,000 |
| Total cash paid for shares withheld for taxes due upon vesting of restricted stock | 40,423 | 713 | 1,917 | 569 | 43,622 | 36,447 |
| Total cash paid for excise tax | - | - | - | 1,108 | 1,108 | - |
| Total cash paid for shares repurchased | $113,834 | $75,712 | $51,604 | $45,216 | $286,366 | $136,447 |
- Remaining Performance Obligations
We disclose revenue that we expect to recognize from our remaining performance obligations ("RPO"). Over 98% of our RPO represents cloud native subscriptions with non-cancelable terms greater than one year (including cloud-deferred revenue as well as amounts we will invoice and recognize as revenue from our performance of cloud services in future periods). Maintenance contracts are typically one year and not included in the RPO. Our RPO as of the end of each period appears below (in thousands):
| March 31, 2024 | June 30, 2024 | September 30, 2024 | December 31, 2024 | March 31, 2025 | |
|---|---|---|---|---|---|
| Remaining Performance Obligations | $1,516,430 | $1,601,531 | $1,686,421 | $1,780,400 | $1,891,384 |